跳至主要内容
临床试验/NCT02172963
NCT02172963已完成1 期

A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis

Karolinska Institutet2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2011年11月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
12
试验地点
2
主要终点
Response at day 28 after onset of hemorrhagic cystitis

研究概览

简要总结

The purpose of this study is to evaluate the safety and efficacy using placenta derived decidual stromal cell therapy for hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. It is hypothesized that the decidual stromal cell therapy is safe to infuse and that they have a positive clinical effect.

详细描述

Patients with grade 2-4 hemorrhagic cystitis will receive decidual stromal cell therapy at approximately 1-2x10^6 cells/kg once or at weekly intervals dependent on clinical effect.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Hemorrhagic cystitis grade 2-4

排除标准

  • Urinary urge without macroscopic hematuria or clots

结局指标

主要结局

Response at day 28 after onset of hemorrhagic cystitis

时间窗: 28 days after inclusion

Disappearance of macroscopic hematuria.

次要结局

  • Time to disappearance of pain or urges(Up to 6 months after inclusion)
  • Actuarial survival at one year after onset of hemorrhagic cystitis(One year after inclusion)
  • Time to disappearance of microscopic hematuria(Up to 84 days after inclusion)
  • Transplant related mortality(Up to one year after inclusion)
  • Incidence of severe infections(Up to one year after inclusion)
  • Incidence of graft versus host disease(Up to one year after inclusion)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Olle Ringdén

Professor

Karolinska Institutet

研究点 (2)

Loading locations...

相似试验

A Pilot Study Using Placenta Derived Decidual... | 临床试验